1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Cboe Europe  -  05/16 10:59:45 am EDT
735.00 DKK   -1.88%
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals

12/28/2021 | 09:27am EDT


ę MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
NASDAQ COMP. -1.28% 11659.22 Real-time Quote.-24.54%
NOVO NORDISK A/S -1.88% 735 Delayed Quote.1.92%
All news about NOVO NORDISK A/S
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
05/11NOVO NORDISK : Deutsche Bank keeps its Buy rating
MD
05/10Novo Nordisk Starts Research Collaboration With Flagship Pioneering
MT
05/09Novo Nordisk - major shareholder announcement
AQ
05/06NOVO NORDISK A/S :
GL
05/06NOVO NORDISK A/S :
GL
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 166 B 23 178 M 23 178 M
Net income 2022 52 637 M 7 367 M 7 367 M
Net cash 2022 4 087 M 572 M 572 M
P/E ratio 2022 32,1x
Yield 2022 1,53%
Capitalization 1 702 B 238 B 238 B
EV / Sales 2022 10,3x
EV / Sales 2023 9,06x
Nbr of Employees 49 295
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 749,10 DKK
Average target price 787,92 DKK
Spread / Average Target 5,18%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S1.92%238 221
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421